🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Recruitingn/aAges any - anyAllZhuhai Trinomab Pharmaceutical Co., Ltd.
NCT07107932 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury; * 2\. Provided signed informed consent by themselves or their legal representatives. Exclusion Criteria: * None
💊

What it tests

  • Siltartoxatug Injection (Brand name: Sintetol®)
📍

Where

4 sites
The Second Affiliated Hospital of Shantou University
Shantou, China
Xiangyun County People's Hospital
Xiangyun, China
Shaoxing Central Hospital
Shaoxing, China
Zhoushan Putuo District People's Hospital
Zhoushan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy